Semaglutide vs Tirzepatide: Which Is Better for Weight Loss?

The Core Difference: Dual vs. Single Agonism

Both medications mimic GLP-1 (glucagon-like peptide-1), a hormone that regulates appetite, insulin release, and gastric emptying. The key distinction:

• Semaglutide — GLP-1 receptor agonist only
• Tirzepatide — GLP-1 + GIP (glucose-dependent insulinotropic polypeptide) dual agonist

By targeting both GLP-1 and GIP receptors, tirzepatide produces a more powerful appetite-suppression effect and appears to improve insulin sensitivity through complementary pathways. This dual mechanism is the reason for the superior weight loss outcomes in clinical trials.

Weight Loss: Head-to-Head Trial Data

SURMOUNT-1 (Tirzepatide)

• 2,539 adults without diabetes
• At 72 weeks: 15 mg tirzepatide → 20.9% average body weight loss
• 37.9% of participants lost ≥25% of body weight

STEP 1 (Semaglutide)

• 1,961 adults without diabetes
• At 68 weeks: 2.4 mg semaglutide → 14.9% average body weight loss
• 32% of participants lost ≥15% of body weight

No direct head-to-head trial exists, but the SURMOUNT-5 trial compared them directly in 2024, confirming tirzepatide's superiority: tirzepatide achieved ~47% more weight loss than semaglutide over 72 weeks.

Side Effects: What's Different

Both medications share a similar GI side effect profile due to GLP-1 agonism:

Common to both:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Constipation or diarrhea
• Decreased appetite

Key differences:

• Tirzepatide's GIP component appears to slightly reduce GI side effects vs. semaglutide at equivalent weight loss — though individual responses vary
• Both carry the same serious contraindications: history of medullary thyroid carcinoma or MEN2, active pancreatitis

Tolerability in SURMOUNT vs. STEP trials:

• Nausea rates were similar (~30% early treatment)
• Discontinuation due to GI side effects: ~4–5% with tirzepatide, ~4–5% with semaglutide

Cost Comparison

For self-pay patients, tirzepatide is decisively cheaper due to Zepbound single-dose vials. For commercially insured patients with savings cards, out-of-pocket cost is similar.

Cardiovascular Outcomes

Semaglutide: The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease. This is the first GLP-1 medication to demonstrate this benefit, and it drove expanded Medicare coverage of Wegovy.

Tirzepatide: The SURPASS-CVOT trial data for cardiovascular outcomes in obesity is ongoing. Tirzepatide has demonstrated strong cardiovascular benefit signals but lacks the same completed CVOT data as semaglutide currently.

If you have established cardiovascular disease, semaglutide has stronger current evidence for CV risk reduction.

Approval Status and Indications

Which Should You Choose?

Choose tirzepatide (Zepbound) if:

• You want maximum weight loss
• You're self-pay and want the most affordable branded option
• You don't have established cardiovascular disease requiring the SELECT trial-proven CV benefit

Choose semaglutide (Wegovy) if:

• You have established cardiovascular disease and want the SELECT trial-proven benefit
• Your insurance covers Wegovy but not Zepbound
• You've already tried tirzepatide and had tolerability issues
• You prefer the longer safety record

Talk to your provider: Individual factors — your comorbidities, insurance coverage, prior treatment history, and tolerability — should drive the final decision.

Bottom Line

Tirzepatide produces approximately 6 percentage points more weight loss than semaglutide in clinical trials, costs less at list price, and has a self-pay vial option for uninsured patients. Semaglutide has stronger cardiovascular outcome evidence and a longer safety track record. For most patients seeking maximum weight loss without established CVD, tirzepatide is the stronger first choice — but both are highly effective medications with similar side effect profiles.

Sources

• Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, 2022
• Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, 2021
• Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM, 2023